Current Perspectives on Spinal Cord Stimulation for the Treatment of Cancer Pain

Introduction

Cancer-related pain is one of the most debilitating and feared symptoms, afflicting approximately nine million cancer patients annually.¹ The etiology of pain in this population is unique and may be related to primary or metastatic disease in two-thirds of patients, whereas other causes including surgery, chemotherapy, radiation, immobility, osteoporosis, and infection may lead to pain in a third of patients.² Pain may be aggravated by mood disorder, fatigue, cachexia, nausea, and other symptoms that commonly manifest in cancer patients.² It is concerning that conventional pharmacologic therapy based on the World Health Organization (WHO) guidelines may fail to achieve acceptable pain relief in 10–15% of cancer patients.^3,4 Furthermore, chronic cancer pain may have a significant neuropathic pain component in up to 40% of patients, which often responds poorly to conventional pharmacologic therapy including opioid-based therapy.⁵

In patients with refractory pain, interventional pain management modalities may provide substantial pain relief. Interventional approaches include common local anesthetic and steroid injections, neuraxial analgesia (intrathecal or epidural catheter), and sympathetic blockade from neurolytic injection and radiofrequency ablation.⁶ More recently, the use of spinal cord stimulation (SCS) and other neuromodulation approaches have been proposed and studied as an indication for cancer-related pain. SCS involves delivery of electric fields between metal electrodes in the epidural space which modulates pain signaling in the spinal cord. The mechanisms by which SCS relieves or modulates pain have been studied extensively. The electrical signals from the SCS electrodes are thought to exert pain-relieving effects by one or more of several mechanisms: increased levels of several dorsal horn neurotransmitters known to modulate pain including serotonin, norepinephrine, gamma-aminobutyric acid, and acetylcholine; suppression or modulation of hyperexcitable or sensitized dorsal horn wide dynamic range neurons that are implicated in many neuropathic pain states; antidromic stimulation of peripheral nerve fibers leading to the peripheral release of vasodilatory neurotransmitters including calcitonin gene-related peptide and nitric oxide; and supraspinal effects. The mechanism of action for dorsal root ganglion (DRG) stimulation appears to be a direct action on abnormally firing primary cell bodies in the DRG. These putative mechanisms are all congruent with the observed clinical pain-relieving effects of SCS and DRG stimulation.^7–9

While our understanding of the underlying mechanisms of analgesia in SCS continues to evolve, studies have established the efficacy of SCS in many non-malignant pain syndromes including failed back surgery syndrome, angina, limb ischemia, painful diabetic peripheral neuropathy, and complex regional pain syndrome.^8–12 However, the efficacy of SCS in cancer-related pain remains understudied and warrants future investigations.

This facet of SCS research is clinically important because inadequately treated cancer pain may have a negative impact on quality of life, which in turn may also exacerbate the severity of pain.^13–15 Untreated pain may lead to unwillingness to comply with treatment plans, leading to therapeutic failure and influencing survival from cancer progression.¹⁶ Higher indirect hospital costs may result from unnecessary hospital admissions, emergency department visits, and need for psychological treatment.¹⁷ Some studies have reported that the severity of cancer-related pain is associated with shorter survival, independent of known prognostic factors.^18,19 While the evidence is mixed, studies also suggest that there may be an association with long-term opioid use and shorter survival in cancer patients, warranting consideration of non-opioid-based therapy and interventional management.²⁰ Recently, SCS has been shown to reduce systemic analgesic and opioid use in patients with intractable chronic pain.²¹

Despite an increasing number of recent clinical trials evaluating the efficacy of SCS for cancer pain, there have been few efforts to systematically synthesize the impact of SCS on analgesic efficacy, patient satisfaction, safety, and opioid consumption in cancer-related pain. In this narrative review, we provide evidence for the use of SCS for the treatment of cancer-related pain, important considerations when planning neuromodulation therapy in this patient population, and areas for future investigation.

Methods

This is a narrative review of the literature regarding the use of SCS in the treatment of cancer pain. The objective was to review the literature to gain an understanding of the potential benefits of SCS therapy in cancer-related pain syndromes. A librarian-assisted literature search of the PubMed, Science Direct, and Google Scholar databases was utilized. The terms “spinal cord stimulation,” “cancer pain,” “oncology,” and “neuromodulation” were searched and potential manuscripts collected. Results were limited to publications in English and a date range was not used. This resulted in finding 127 articles. Additionally, the literature search was supplemented by review of former systematic and narrative reviews. Manuscripts were excluded if they were meta-analyses, reviews, or study rationales, or if they were not related to the desired subject matter. Studies regarding anesthesia during surgery were also excluded. After abstract and full manuscript review, a total of 17 articles were included in this review.

Review of Cancer-Related Pain and SCS

There are significant challenges associated with cancer-related pain diagnosis and treatment given the heterogeneous nature of pain presentation and the individual experience. The focus of this discussion will review the use of spinal cord stimulation for the treatment of chronic cancer pain syndromes as it relates to tumor-related pain syndromes affecting the nociceptive (somatic and visceral) and neuropathic aspects of cancer-related pain.

Greater than 75% of cancer patients suffer chronic pain related to the direct effects of their malignancy.²² When treating pain, it is helpful to try to identify the source of pain as that typically allows for a more targeted therapeutic intervention. Unfortunately, a significant proportion of cancer patients continue to suffer from under-treated pain symptoms, which has driven much research into the use of SCS as a treatment option for the nociceptive and neuropathic pain syndromes. The primary drivers for somatic nociceptive pain arise from primary osseous lesions, as well as secondary bone metastases and multifocal bone metastases including the axial and appendicular skeletal systems. The pain often associated with bony involvement may be due to numerous factors, including direct cortical invasion of the tumor, pathologic fracture of a weight-bearing segment or long bone, or inflammation and distortion of the neurobiological milieu of the primary and surrounding tissues, as is often seen in hematologic malignancies.^23,24 As pain is often an early symptom prior to functional loss or neurologic impairment, it is paramount to identify these underlying concerning lesions and offer symptomatic treatment.²⁵ Although no studies to date have specifically evaluated the use of SCS for the treatment of refractory somatic cancer-related bone pain, there have been case reports and case series noting significant improvements in the patients’ reported pain outcomes (Table 1). Mirpuri et al discussed a single female with hereditary osteochondromas who failed conventional medical management and was successfully treated with SCS.²⁶ This case demonstrated the important early research into multifactorial bone pain and the potential for opioid reduction and improvement in activities of daily living. Hutson et al reported a case series focused on different forms of interventional therapies for sacroiliac tumors. The authors reported that SCS resulted in improved pain scores, physical performance, and opioid cessation for the patient that received SCS as a definitive therapy.²⁷ Although SCS is most often used for neuropathic pain syndromes, growing reports such as this describe its role in targeting of dorsal column pathways that are implicated in nociceptive pain syndromes.

Table 1 Publications Discussing the Use of Spinal Cord Stimulation for Cancer-Related Chronic Pain

Viscerosomatic pain syndromes present another challenging subset of cancer-related pain. Pain of this nature is often seen in patients with chronic abdominopelvic pain from neoplasm-related injury to the peritoneal organs, soft tissue invasion from thoracic and pleural malignancies, and even dysmotility of hollow viscus organs which is common in patients with gastrointestinal or gynecologic malignancies. Typical provocation of visceral pain results in a dull, boring, non-focal and non-specific pain. Given the neurophysiologic convergence of nociceptive afferent input with classic neuropathic fibers, specifically the sympathetic and parasympathetic nervous system, the primary intent of an intervention is to target the various sympathetic nervous system ganglia with secondary intention to disrupt the nociceptive transmission of pain. It is important to understand that visceral sensory afferents are primarily thinly myelinated Aδ and unmyelinated C-fibers, which can become highly sensitized thus leading to altered nociceptive processing. The mechanistic rationale for targeting the central convergence pathway with dorsal column stimulation stems from basic science research that has demonstrated reduction of centrally amplified highly sensitized neuronal tissue through neuroelectrophysiologic changes that occur in the spinal cord and supraspinal neurologic centers.^28–31 As with somatic-related cancer pain syndromes, the use of SCS for viscerally mediated cancer pain has not been formally evaluated. A number of case reports have suggested successful use of SCS for treatment of refractory viscerally mediated cancer-related pain with improvements in pain scores, functional performance, and opioid reduction.^30–32 Clearly, the communication between the somatic and neuropathic systems is more integrally related than is commonly appreciated and much of the soundest research available stems from the well-established role SCS plays in treatment of neuropathic pain.

Tumor-related neuropathic pain syndromes most often are caused by direct tumor invasion of the peripheral nerves, plexuses, nerve roots and central nervous system. The simple act of neural compression, destruction, or inflammation may lead to the typical neuropathic pain symptoms including paroxysmal aching or sharp sensations, burning or electrical dysesthetic pain, and may or may not be associated with functional or motor changes. The location and presentation of symptoms depend on the neural structure being affected. Focal mononeuropathies may be more isolated to a peripheral nerve distribution, whereas a polyneuropathy or plexopathy may present with more diffuse circumferential or patchy pain. Spinal cord injury often presents with a burning dysesthetic pain in the area localized to the injury or the long tracts leading to appendicular symptoms. Given the diverse nature of cancer-related neuropathic pain, it presents many challenges to successful treatment and remains largely refractory to conservative medical management and pharmacologic treatment. The use of SCS for the treatment of cancer-related neuropathic pain is of great interest. Dating back nearly half a century to the first SCS device in the late 1960s, the use of SCS to change the nociceptive spinothalamic signaling pathway has shown promising results.³³ Numerous case reports and series have demonstrated an improvement in pain intensity, reduced opioid consumption, and improvement in daily performance for various cancer-related neuropathic pain syndromes including low back pain, lower extremity peripheral neuropathy, and spinal cord injury.^{4,30,31,34–40} Despite the lack of a randomized control trial leading to the suggestion that current evidence is insufficient for the role of SCS in the cancer pain population, the most recent systematic review found that over 80% of patients reported at least 50% reduction of pain and decreased use of opioid medications.⁴¹ This simply summarizes the need to develop future research to assess the efficacy of SCS for the treatment of cancer-related pain in a prospective fashion.

While the literature supporting the use of SCS for the treatment of cancer-related somatic and neuropathic pain continues to mature, the treatment of individuals with refractory cancer-related pain remains paramount. Although the exact mechanism is not completely understood, one must recognize that the use of SCS likely targets central and supraspinal centers through multiple different unique actions including mediation of wide dynamic range neurons, the complex inter-neuronal glial network, and alterations in the pain pathway neurotransmitters.^42,43 By targeting the nociceptive fibers in the dorsal horn and spinothalamic pathways with electrical energy, one may reduce the excitability seen with tumor-related somatic and neuropathic cancer pain syndromes leading to improved pain intensity, reduced opioid consumption, and improved physical performance.

Review of Cancer Treatment-Related Pain and SCS

Treatment of cancer including surgery, radiation, and chemotherapy can result in a number of pain syndromes. Pain due to cancer treatment contributes to more than 70% of patients who report cancer-associated pain, including 40% of patients reporting neuropathic pain.⁴⁴ Pain following cancer treatment can be categorized as neuropathic or nociceptive, with or without predominant features of central sensitization.⁴⁵ Pain that is disproportionate to the underlying injury or pathology, does not follow logical anatomical distribution, and is characterized by hypersensitivity or allodynia, may represent the development of central sensitization following cancer treatment. Pain related to cancer treatment may be refractory to pharmacologic agents and more conservative interventions, and in such cases neuromodulation may be considered.^38,39

Chemotherapy can result in a number of acute and chronic pain syndromes in cancer patients.⁴⁶ Almost 75% of patients with cancer who have pain have neuropathic or nociceptive symptoms directly related to their cancer, but chronic pain is known to occur as a result of cancer treatment as well, sometimes months or even years after therapy. Pain related to hormonal therapies can manifest as arthralgias, dyspareunia, gynecomastia, myalgias, and osteoporotic compression fractures. Pain due to radiation may result in chest wall pain, cystitis, osteoporotic fractures, painful secondary malignancies, myelopathy, painful plexopathies, and peripheral mononeuropathies.⁴⁶ Symptoms may be localized to the area of treatment or be more generalized in the case of some secondary malignancies. Radiation myelopathy can present with symptoms similar to spinal cord injury including neuropathic pain as well as other sensory and/or motor symptoms. Peripheral neuropathy is a well-known complication of chemotherapy but other pain syndromes can result including avascular necrosis, vertebral compression fractures, and carpal tunnel syndrome. Bony complications can result from long-term corticosteroid use and are often painful. Examples of pain following cancer surgery include painful lymphedema, residual limb pain following amputation (including phantom limb pain), and pelvic floor pain after gynecologic surgery, as well as surgical site pain from laparotomy, mastectomy, radical neck dissection, or thoracotomy. Pain related to cancer treatment can manifest in many different syndromes at multiple time points. Awareness of this type of cancer-associated pain is important for understanding its relationship to the patient’s disease process, whether its distribution is logical or expected, and whether it may be expected to put a patient at risk for central sensitization.

A number of case reports and case series report successful treatment of chemotherapy-associated neuropathic pain (Table 2).^34,47 Cata et al described the successful utilization of SCS in two patients with severe neuropathic pain of the lower limbs following systemic chemotherapy refractory to medications including opioid and anti-seizure medications.³⁴ The authors carefully assessed neuropathic pain symptom burden incorporating the use of quantitative sensory testing prior to SCS trial in order to ascertain the degree of neuropathic pain. Abd-Elsayed et al reported successful treatment of chemotherapy-associated neuropathic pain in the setting of breast cancer with SCS.⁴⁷ Ting et al described the use of SCS to treat cisplatin-induced Raynaud’s syndrome resulting in bilateral progressive upper extremity digital ischemia requiring distal phalangeal amputation. The patient experienced significant improvement in pain symptoms as well as ulcer healing.⁴⁸

Table 2 Publications Discussing the Use of Spinal Cord Stimulation for Cancer Treatment-Related Chronic Pain

Radiation therapy can result in a number of iatrogenic nerve injuries including plexopathies, myelopathy, and peripheral mononeuropathies. Elahi et al described the successful treatment of pudendal entrapment neuropathy following pelvic radiation therapy in a patient with stage IV prostate cancer utilizing dorsal column SCS.⁴⁹ Hamid et al utilized surgically placed dorsal column SCS for treatment of bilateral lower extremity pain in the setting of transverse myelitis developing after radiation therapy for non-small cell lung carcinoma.⁵⁰ Painful complications of radiation therapy can result in particularly intractable symptoms in many patients, and it is important to recognize symptoms of central or peripheral nerve pain that might be expected to manifest in patients treated with radiation therapy.

Chronic pain following surgical treatment for cancer can result in nociceptive or neuropathic pain; however, the literature consists mainly of reports of neuromodulation being used to treat primarily neuropathic pain only. Goyal et al described the successful utilization of peripheral field stimulation for post-thoracotomy scar pain.⁵¹ The patient initially had a robustly positive response to intercostal nerve block using anesthetic although benefits were short-lived. Wininger et al treated post-thoracotomy pain in a patient treated for non-small cell lung cancer using SCS, with the patient reporting 75% relief 2 years following implant.⁵² Neuromodulation is commonly applied in post-amputation phantom limb pain, and Viswanathan et al describe a series of four patients with phantom limb pain following lower limb amputation of cancerous tumors. All four patients experienced at least 80% pain relief, although one developed an allergic reaction to the IPG and the other a surgical site infection following routine exchange of the IPG.⁵³ Dorsal column SCS has been employed to treat lower extremity neuropathic pain developing after T5 spinal meningioma removal.⁵⁴ Patients undergoing surgery for malignancy may not necessarily be at higher risk for chronic pain, but certainly the complexity of surgery and possibly related comorbidities can result in pain syndromes not commonly seen in patients without a history of cancer.

As an indicated therapy for intractable neuropathic pain of the trunk and/or extremities, patients with cancer treatment-associated pain may be candidates for this type of advanced intervention. Particularly in patients who have undergone successful treatment and have normal life expectancy, non-opioid-based interventions such as neuromodulation are attractive options for improving pain and quality of life in patients experiencing chronic pain following cancer treatment. An updated systematic review of spinal cord stimulation for cancer-associated pain did not find sufficient high-quality evidence to recommend neuromodulation as a superior therapy to pharmacologic agents for treating cancer-related pain.⁴¹ To the best of our knowledge with a librarian-assisted literature search strategy, the authors did not find a single randomized controlled trial assessing the safety or efficacy of neuromodulation for cancer-associated pain, and our current review did not identify any new trials since this review was published in 2015. While we are optimistic about the use of neuromodulation for cancer-treatment-related pain, more evidence is needed to assess the safety and efficacy of neuromodulation in this patient population.

Precautions in Cancer Pain Patients Receiving SCS

Given the consequences of cancer and cancer treatments on hemostasis of the body, precautions should be undertaken to avoid complications. Specifically, immunosuppression, coagulopathy, and the potential for poor wound healing need to be considered. We will consider each of these areas below.

Immunosuppression

Cancer immunosuppression can occur from cancer-mediated factors or from treatment-related effects. Cancer cells create an immunosuppressive network secondary to secretion of tumor-derived soluble factors (TDSFs), such as interleukin-10 (IL-10), transforming growth factor-beta (TGF-beta), and vascular endothelial growth factor (VEGF).⁵⁵ These factors promote creation of immature myeloid cells and T cells, which are attracted to the cancer site. Upon arrival, they are biochemically modulated causing inhibition of dendritic cell maturation and functional inhibition of T-cells and NK-cells.⁵⁶ Because of these changes, there is impaired phagocytosis and clearance of apoptotic cells, which induces anti-DNA antibodies and a condition resembling autoimmune disease.⁵⁵ Altogether, these immunosuppressive changes increase the risk of post-operative infections, in addition to tumor progression.

When considering infection risk based on cancer type, hematologic malignancies are associated with an increased risk overall. Due to functional asplenia, hypogammaglobulinemia, and impaired B-cell immunity, these patients have an increased risk of encapsulated bacterial infections.⁵⁷ They are also at risk of mycobacterial and viral infections given defective T-cell immunity. If myelodysplastic syndrome develops, this places the patient at increased risk of bacterial, viral, and fungal infections related to neutropenia.⁵⁷

Cancer treatments can also place patients at an increased risk of infection. Radiation has been shown to increase production of TGF-beta on a per cell basis.⁵⁶ As mentioned earlier, elevated TGF-beta causes immunosuppression. Chemotherapy causes neutropenia (absolute neutrophil count [ANC] <500 cells/mm³) and decreased granulocytes may encourage bacterial and fungal infections.^57,58 Nucleoside analogs cause T-cell depletion and increase risk of bacterial and viral infections. Alemtuzumab causes a broad defect in host immune defenses, which leads to risk of bacterial, viral, and fungal infections. Rituximab decreases B-cell immunity, which poses a risk of bacterial infections. Other drugs inhibit cytokine signaling (ex. Infliximab), which increases the risk of bacterial, viral, and fungal infections. Lastly, calcineurin inhibitors cause defective T-cell immunity that puts the patient at risk of viral infections.⁵⁷ We advise close inspection of the patient’s chemotherapeutic drug regimen to properly determine immunologic risks.

Autologous hematopoietic stem cell transplantation causes weeks of neutropenia, which is followed by weeks or months of defective T-cell immunity. This may increase the risk of bacterial infections in the short-term and viral infections over time. Allogeneic transplantation is even more complex. Depending on a number of factors, particularly those related to the transplant match and graft-versus-host-disease prophylaxis, these patients are at an increased risk of infection for months afterwards from a variety of organisms.^57,58

Coagulopathy

Thrombotic and bleeding complications are not uncommon in cancer and it involves a complex interplay of underlying mechanisms. Given the prothrombotic properties of tumor cells and microvascular dysfunction, venous thromboembolism occurs in approximately 20% of patients and is the second most common cause of death in this patient population.⁵⁹ Due to increased clotting, there is a consumptive coagulopathy present that leads to a disorder of coagulation, particularly involving platelets and the complement system. Similar to disseminated intravascular coagulation, but less severe given its chronic and gradual progression, these patients are at risk of significant bleeding following minor skin breaches, including surgical incisions.⁶⁰

Compromised Wound Healing

Cancer and its treatments cause significant physiologic changes. Given the wide range of treatment options, including surgery, radiation, and chemotherapeutic agents, wound healing becomes critically important in the continuum of cancer care. Wound healing involves a myriad of interweaving processes, and any cancer or treatment-related disruption in this progression can affect the body’s healing abilities.

Nutrition plays an important role in cancer care and the healing process. It is well documented that positive nutritional balance promotes optimal wound healing, and physicians must consider this when considering surgical intervention.⁶¹ Malnourished patients have an increased susceptibility to surgical site complications, including infection and delayed wound healing. Nutritional supplementation, specifically fluids, vitamins (especially Vitamins C and A), protein, fat, carbohydrates, and overall calories, should be considered in cancer patients to minimize or reverse the negative consequences of malnutrition. In order to provide this, enteral or parenteral routes may need to be employed. Prealbumin and albumin levels should be considered in all patients preoperatively and in those individuals presenting with nonhealing wounds.⁶¹

Treatment-related effects on wound healing must also be considered. Radiotherapy causes ionization and subsequent cellular damage to vital structures. High-turnover cells are more susceptible to this damage, including epithelial cells, and this may lead to delayed wound healing at sites of radiation.^61–63 Chemotherapy is a common and essential treatment in cancer care. Similar to radiotherapy, chemotherapeutic agents preferentially target rapidly dividing cells, and this includes tissues involved with incisional healing.^61,64 VEGF inhibitors are particularly detrimental to wound healing given the known effects on angiogenesis.^65,66 Corticosteroids are often employed for patients with cancer to assist with pain control; however, early administration following surgery has been shown to have negative consequences on wound tensile strength.⁶¹ This is caused by the expected anti-inflammatory response of corticosteroids, which suppresses the progression of wound healing.

Future Directions

Cancer-related pain represents an important public health problem in terms of the number of patients afflicted and health care costs.⁶⁷ Most patients with cancer-related pain are treated with opioid and non-opioid medications as the mainstays of therapy, and yet many medically treated patients continue to report ongoing pain and decreased quality of life.⁶⁸ Additionally, adverse effects from pain-related medications represent a considerable challenge for clinicians and patients. Central nervous system and gastrointestinal side effects, in particular, are common and often lead to significant patient morbidity and impaired quality of life.^69–71

SCS obtained US Food and Drug Administration approval in 1989, for the treatment of intractable pain of the trunk and/or limbs.⁸ Since then, the device hardware, technology, and software contained within the impulse generators have drastically improved and along with that, patient outcomes have improved as well.⁷² SCS has been demonstrated in several RCTs totaling over 1000 patients, to provide improved pain control when compared to medical therapy in many challenging chronic neuropathic pain conditions including chronic spine pain persisting after surgery, painful diabetic neuropathy, complex regional pain syndrome, and pain in the setting of peripheral vascular disease.¹² The therapy appears to provide effective pain control across a variety of neuropathic pain conditions and pain-inducing mechanisms. There is an important need to study SCS in cancer-related pain conditions, particularly when considering the shortcomings of the current published literature in this area (including retrospective study designs, small patient numbers, and no inclusion of neurostimulation technological advancements). However, based upon the experience with SCS in the non-cancer pain population and on small series and case reports in cancer pain, it seems highly likely that SCS can be a useful and effective therapy in many of the challenging cancer-related neuropathic pain syndromes such as post radiation neuropathic pain, chemotherapy-induced peripheral neuropathies, and post-surgical pain syndromes.^4,52,73

This is especially important going forward: as cancer survival rates continue to increase, patients who are afflicted with these debilitating pain conditions may endure long periods of pain and suffering if the underlying pain problem is not optimally treated.⁷⁴ Clinical trials comparing conventional medical therapy to SCS for the aforementioned pain syndromes are needed and would have the highest impact for the greatest number of patients. Additionally, assessment of patient-related characteristics that predict successful therapeutic response from SCS should also be evaluated with a focus on demographic predictor variables (ie, age, gender), type and stage of cancer, type of pain (ie, somatic, visceral, neuropathic), pre-procedural opioid use, and other comorbidities (ie, psychiatric disorder). Until then, patients with intractable pain despite maximal medical therapy should be referred to an interventional pain specialist to assess for candidacy of advanced interventional treatment options such as SCS.

Lastly, specific timing for safe SCS use in the setting of ongoing cancer-related treatment requires study. As discussed above, these situations are complex and many aspects of patient care are affected. Currently, the authors would recommend following institutional guidelines and having clear communication with the entire care team to ensure optimal patient outcomes and minimize complications. Similarly, the need for future cancer surveillance imaging requires consideration as this may influence device selection.⁷⁵

Conclusion

Cancer and cancer treatment-related chronic pain affect a significant number of oncologic patients and this is likely to increase in the coming years as survival is enhanced. While these symptoms have traditionally been managed with medications, injections, and neuraxial therapies, there is low-level evidence that SCS and DRG stimulation should be considered as an additional therapeutic option. When considering evidence from non-cancer pain studies, there is Level 1 evidence to support the use of SCS and DRG stimulation in chronic neuropathic pain states. Given the similarities in pain quality found in many cancer patients, it is crucial that we research and explore this therapeutic option in the cancer pain population.